Evidence map›Paper›PMID 41310398›Full record

ArticleCommunications chemistry2025

Using phage display for rational engineering of a higher-affinity humanized 3' phosphohistidine-specific antibody.

Gregory D Martyn, Rajasree Kalagiri, Gianluca Veggiani, Robyn L Stanfield, Indrani Choudhuri, Margaux Sala, Jill Meisenhelder, Chao Chen, Avik Biswas, Ronald M Levy and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Gregory D Martyn *School of Pharmacy, University of Waterloo, Kitchener, ON, Canada.
Rajasree Kalagiri *Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.
Gianluca Veggiani *School of Pharmacy, University of Waterloo, Kitchener, ON, Canada.ORCID http://orcid.org/0000-0002-4064-0112
Robyn L Stanfield *Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Indrani ChoudhuriLaboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA, USA.
Margaux SalaMolecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3483-361X
Jill MeisenhelderMolecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.
Chao ChenSchool of Pharmacy, University of Waterloo, Kitchener, ON, Canada.
Avik BiswasLaboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3519-3944
Ronald M LevyCenter for Biophysics and Computational Biology, and Department of Chemistry, Temple University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8696-5177
Dmitry LyumkisLaboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-8124-7472
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6469-2419
Tony HunterMolecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA. hunter@salk.edu.ORCID http://orcid.org/0000-0002-7691-6993
Sachdev S SidhuSchool of Pharmacy, University of Waterloo, Kitchener, ON, Canada. sachdev.sidhu@uwaterloo.ca.ORCID http://orcid.org/0000-0001-7755-5918

Funding

Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Reuben Shaw · 1985 to 2026
$82.8M
User Training & OutreachP30GM138396 · NIGMS · UCHICAGO ARGONNE, LLC · PI ROBERT F. FISCHETTI, JANET L. SMITH · 2020 to 2026
$34.3M
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Histidine phosphorylation as a new target for cancer therapyR35CA242443 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI HUNTER, TONY R. · 2019 to 2025
$7.5M
Structural basis for activity of and resistance to HIV integrase inhibitorsU01AI136680 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI LYUMKIS, DMITRY · 2022 to 2025
$3.4M
Mapping Fitness & Free Energy Landscapes of ProteinsR35GM132090 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI Ronald Levy · 2019 to 2026
$3.2M
High-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0M
Pilatus 6mS10OD021832 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI ADAMS, PAUL DAVID · 2016 to 2016
$980k
NCI NIH HHS P30 CA014195NCI NIH HHS R35 CA242443NIAID NIH HHS U01 AI136680NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30 GM138396NIGMS NIH HHS P41 GM103393NIGMS NIH HHS R35 GM132090NIH HHS S10 OD012289NIH HHS S10 OD021832ODCDC CDC HHS S10 OD012289U.S. Department of Energy (DOE) DE-AC02-05CH11231U.S. Department of Energy (DOE) DE-AC02-06CH11357U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 5 R35 CA242443U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) ACB-12002U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) AGM-12006U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) P30GM138396U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) P41GM103393
6 · The paper itself

Abstract

Histidine phosphorylation is a non-canonical post-translational modification (PTM), with 1-phosphohistidine (1-pHis) and 3-phosphohistidine (3-pHis) isoforms, that is understudied due to a lack of robust reagents, including high-affinity pHis-specific antibodies. Engineering pHis antibodies is challenging due to the labile nature of its phosphoramidate (P-N) bond. We developed a strategy for in vitro engineering of antibodies for the detection of native 3-pHis targets, in which the rabbit SC44-8 anti-3-pTza mAb is humanized into a scaffold (hSC44) that is suitable for phage display. Six unique Fab phage-displayed hSC44 scaffold libraries were screened for antibodies that bound 3-pHis with higher affinity and had specificity for 3-pHis versus 3-pTza. hSC44.20N32F

Identifiers

PMID41310398
PMCPMC12660843

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.